FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978584847> ?p ?o ?g. }

• W1978584847 endingPage "68" @default.
• W1978584847 startingPage "67" @default.
• W1978584847 abstract "Traditionally, pediatric patients are prophylaxed against acute graft-versus-host disease (GvHD) with cyclosporine combined with either methotrexate Mtx) or methylprednisolone (Pred). Mtx worsens the severity of mucositis and renal insufficiency while pred causes muscle wasting, hypertension and increased infections. Cellcept (myophenolic acid) is a better tolerated, less toxic agent with synergistic immunosuppressive effects when combined with cyclosporine or tacrolimus. We explored its use in combination with cyclosporine in 21 pediatric patients undergoing allogeneic transplantation. Patients with both malignant (n = 7) and non-malignant (n = 14) conditions ranging in age from 2 weeks to 15 years were transplanted after myeloablative preparative regimens with either related bone marrow or cord blood (n = 7) or unrelated cord blood (n = 14), using cellcept and cyclosporine for GVHD prophylaxis. Cellcept and cyclosporine were administered intravenously through the first 40-60 days post transplant using cellcept at a dose of 15mg/kg/dose IV q8H beginning on day -2 or -3. The patient then transitioned to oral therapy at the same dose and schedule. There were no acute toxicities attributable to cellcept observed in patients on IV therapy. All patients required treatment with antihypertensive therapy(ies). Grossly infection rates did not vary from those previously observed in conventionally treated patients at our center. 18/21 patients engrafted neutrophils between day 9 and 52. Of the three patients who did not engraft, 2 died of infectious complications, one died of VOD and multi-system organ failure. Of the 18 patients, evaluable for GvHD follow-up ranged between 34 and 693 days (median 108 days), 6 patients had 0 grade I, 10 developed grade II, 1 grade III, and 1 grade 4 GVHD. Follow-up is too short to comment on the incidence of chronic GvHD, but to date, 4 of 7 patients followed for >100 days have developed chronic GvHD. While this data is early, it appears that the incidence of both acute and chronic GvHD are increased compared to previously reported series in patients treated with cellcept instead of mtx (related bone marrow transplantation) or pred (unrelated cord blood transplantation). Engraftment in UCBT recipients was not compromised with the use of IV cellcept administered in the peritransplant period. Additional patients will need to be tested with this regimen and longer follow-up is necessary to fully define the risks or benefits of this therapy." @default.
• W1978584847 created "2016-06-24" @default.
• W1978584847 creator A5012936889 @default.
• W1978584847 creator A5015266579 @default.
• W1978584847 creator A5045608980 @default.
• W1978584847 creator A5053944563 @default.
• W1978584847 creator A5060384074 @default.
• W1978584847 creator A5081348202 @default.
• W1978584847 creator A5090212849 @default.
• W1978584847 date "2006-02-01" @default.
• W1978584847 modified "2023-10-18" @default.
• W1978584847 title "Cellcept/cyclosporine as prophylaxis against graft- versus-host disease in pediatric patients undergoing allogeneic stem cell transplantation" @default.
• W1978584847 doi "https://doi.org/10.1016/j.bbmt.2005.11.212" @default.
• W1978584847 hasPublicationYear "2006" @default.
• W1978584847 type Work @default.
• W1978584847 sameAs 1978584847 @default.
• W1978584847 citedByCount "0" @default.
• W1978584847 crossrefType "journal-article" @default.
• W1978584847 hasAuthorship W1978584847A5012936889 @default.
• W1978584847 hasAuthorship W1978584847A5015266579 @default.
• W1978584847 hasAuthorship W1978584847A5045608980 @default.
• W1978584847 hasAuthorship W1978584847A5053944563 @default.
• W1978584847 hasAuthorship W1978584847A5060384074 @default.
• W1978584847 hasAuthorship W1978584847A5081348202 @default.
• W1978584847 hasAuthorship W1978584847A5090212849 @default.
• W1978584847 hasBestOaLocation W19785848471 @default.
• W1978584847 hasConcept C126322002 @default.
• W1978584847 hasConcept C141071460 @default.
• W1978584847 hasConcept C2779972918 @default.
• W1978584847 hasConcept C2780648854 @default.
• W1978584847 hasConcept C2781059491 @default.
• W1978584847 hasConcept C2909675724 @default.
• W1978584847 hasConcept C2911091166 @default.
• W1978584847 hasConcept C71924100 @default.
• W1978584847 hasConcept C90924648 @default.
• W1978584847 hasConceptScore W1978584847C126322002 @default.
• W1978584847 hasConceptScore W1978584847C141071460 @default.
• W1978584847 hasConceptScore W1978584847C2779972918 @default.
• W1978584847 hasConceptScore W1978584847C2780648854 @default.
• W1978584847 hasConceptScore W1978584847C2781059491 @default.
• W1978584847 hasConceptScore W1978584847C2909675724 @default.
• W1978584847 hasConceptScore W1978584847C2911091166 @default.
• W1978584847 hasConceptScore W1978584847C71924100 @default.
• W1978584847 hasConceptScore W1978584847C90924648 @default.
• W1978584847 hasIssue "2" @default.
• W1978584847 hasLocation W19785848471 @default.
• W1978584847 hasOpenAccess W1978584847 @default.
• W1978584847 hasPrimaryLocation W19785848471 @default.
• W1978584847 hasRelatedWork W2051565853 @default.
• W1978584847 hasRelatedWork W2078240157 @default.
• W1978584847 hasRelatedWork W2086678484 @default.
• W1978584847 hasRelatedWork W2089532890 @default.
• W1978584847 hasRelatedWork W2091592676 @default.
• W1978584847 hasRelatedWork W2121876275 @default.
• W1978584847 hasRelatedWork W2158815868 @default.
• W1978584847 hasRelatedWork W2285404915 @default.
• W1978584847 hasRelatedWork W2575667278 @default.
• W1978584847 hasRelatedWork W2758508779 @default.
• W1978584847 hasVolume "12" @default.
• W1978584847 isParatext "false" @default.
• W1978584847 isRetracted "false" @default.
• W1978584847 magId "1978584847" @default.
• W1978584847 workType "article" @default.